Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abramson Cancer Center at Penn Medicine
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient capable of giving informed consent
Patient diagnosed with hepatocellular carcinoma in both lobes of the liver by one of the following methods (Pathologically confirmed HCC by biopsy or HCC 2 cm with classic radiographic findings of arterial phase enhancement with venous phase washout and pseudocapsule formation on contrast enhanced MRI or CT or Lesion greater than 2 cm with probable imaging features of HCC and imaging findings of cirrhosis and/or portal hypertension or a serum alphafetoprotein (AFP) greater than 200 mg/mL.
Patient not candidate for orthotopic liver transplantation at the Hospital of the University of Pennsylvania based on review of patient imaging and history at multidisciplinary Hepatic Tumor Conference at the Hospital of the University of Pennsylvania.
Age 18 years old
Albumin 2.4 g/dL; Total bilirubin 2 mg/dL; INR 1.5
Creatinine 2.0 mg/dL, AST 121 IU/L; ALT 189 IU/L
Child-Turcotte-Pugh Classification A or B
Eastern Clinical Oncology Group performance status 0 or1.
You may not be if
Prior TACE
Active GI hemorrhage within 2 weeks of study enrollment
Ascites refractory to medical therapy
Contraindication to receiving HCQ or TACE
Unilobar HCC
Contraindication to contrast enhanced MRI (i.e. unable to undergo follow-up imaging)
Women who are pregnant
Participation in another concurrent treatment protocol
